Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity

Observational, Prospective, Multicentric Study of the Effect of Bifidobacterium Longum 35624 on Quality of Life of Patients With Irritable Bowel Syndrome

The main objective of this observatory is to evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity

This observatory evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity, after a one-month treatment with Bibidobacterium longum 35624, 1x10^9 CFU/capsule, 1 capsule/day.

Inclusion Criteria:

• Male or female, at least 18 years of age
• Gastroenterology consultation for an Irritable Bowel Syndrome according to Rome IV criteria
• Having received a first prescription of Bifidobacterium longum 35624 during the consultation (independently of participation in the observatory)
• Informed and having declared his/her non-opposition to the study.

Exclusion Criteria:

• Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook
• Having already taken Bifidobacterium longum 35624
• Having received probiotics or antibiotics within 2 weeks previous
• Having started within the last 7 days a treatment that can interfere with the investigator's evaluation of the investigational product under investigation
• Participant in another trial
• Pregnant or breastfeeding women
• Being under guardianship or curator.
• Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook